BMS’ Opdivo-Yervoy treatment improves survival in hepatocellular carcinoma trial
Patients in the dual immunotherapy arm had a median overall survival of 23.7 months.
05 June 2024
05 June 2024
Patients in the dual immunotherapy arm had a median overall survival of 23.7 months.
TrialHub, the pioneering data intelligence platform known for its innovative use of NLP and AI technologies in clinical trial management, is thrilled to announce a strategic partnership with Biomapas, a global provider of integrated clinical, regulatory, pharmacovigilance, and medical information services. This collaboration marks a significant step forward in enhancing clinical research methodologies and accelerating patient-centric trials.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.